The material continues to be investigated during the patent literature for its anxiolytic Homes and diminished sedative, hypnotic, and ataxic side-outcomes, but it does not look like licensed for health-related use. ?ukasik-G?ebocka et alThe consequences have been generally compared to Those people of flunitrazepam (Rohypnol), but most appeared to